Spanish Menopause Society position statement: Use of denosumab in postmenopausal women.
Por:
Cano A, Silvan JM, Estévez A, Baró F, Villero J, Quereda F, Ferrer J, Mendoza N, Sánchez-Borrego R and Spanish Menopause Society
Publicada:
1 sep 2014
Resumen:
Denosumab is a new drug developed for the treatment of osteoporosis. Moreover, increasing evidences link denosumab with benefits in cancer, an area of interest for those in charge of the postmenopausal health. Denosumab has shown efficacy in the control of bone loss associated with hypogonadic states created by chemotherapy in breast and other cancers. Moreover, some studies reveal efficacy in reducing the progression of metastases. A panel of experts from the Spanish Menopause Society has met to develop usage recommendations based on the best available evidence.
Filiaciones:
:
Obstetricia y Ginecología. Hospital Universitario Dr Peset, University of Valencia, Valencia, Spain
Silvan JM:
Hospital Universitario Virgen del Rocío, University of Seville, Seville, Spain
Estévez A:
Hospital Universitario de Valme, Seville, Spain
Baró F:
Hospital Vall d´Hebron, University of Barcelone, Barcelone, Spain
Villero J:
Hospital Reina Sofía, Córdoba, Spain
:
Obstetricia y Ginecología. Hospital Universitario San Juan, Alicante, University Miguel Hernández, Alicante, Spain
Ferrer J:
Hospital Universitario Central de Asturias, University of Oviedo, Spain
Mendoza N:
Clinica Margen, Department of Obstetrics and Gynecology, University of Granada, Granada, Spain
Sánchez-Borrego R:
Clínica Diatros, Barcelone, Spain
|